Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QNRX | US
0.01
1.72%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.86
0.82
0.94
0.77
Quoin Pharmaceuticals Ltd. a clinical stage specialty pharmaceutical company focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003 a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn Virginia.
View LessPositive Momentum
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
311.9%1 month
236.5%3 months
169.3%6 months
126.4%-
-
0.45
0.43
0.23
-0.42
-
-
-8.84M
3.44M
3.44M
-
-
-
-
-100.03
0.01
0.38
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.09
Range1M
1.09
Range3M
1.09
Rel. volume
0.41
Price X volume
2.36M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Oragenics Inc | OGEN | Biotechnology | 0.345 | 3.63M | 5.83% | n/a | 0.00% |
Virpax Pharmaceuticals Inc | VRPX | Biotechnology | 0.7216 | 3.53M | 6.15% | n/a | 0.00% |
Biodexa Pharmaceticals | BDRX | Biotechnology | 5.98 | 3.47M | 4.91% | n/a | 0.00% |
Alaunos Therapeutics Inc | TCRT | Biotechnology | 2.16 | 3.46M | -4.42% | n/a | 0.00% |
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Aptevo Therapeutics Inc | APVO | Biotechnology | 0.2389 | 3.21M | 20.35% | n/a | 112.59% |
Galera Therapeutics Inc | GRTX | Biotechnology | 0.0555 | 3.07M | 2.78% | n/a | -0.87% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Hiru Corporation | HIRU | Biotechnology | 0.0016 | 3.02M | -15.79% | n/a | 263.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.42 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.45 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 169.28 | 72.80 | Riskier |
Debt to Equity | 0.43 | -1.23 | Expensive |
Debt to Assets | 0.23 | 0.25 | Par |
Market Cap | 3.44M | 3.66B | Emerging |